ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta.

We have studied the role of ATP binding cassette (ABC) transporters in fetal exposure to carcinogens using 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) a known substrate for ABC transporters as a model compound. In perfusion of human term placenta, transfer of (14)C-PhIP (2 microM) through the placenta resulted in fetal-to-maternal concentration ratio (FM ratio) of 0.72+/-0.09 at 6 h. The specific ABCG2 inhibitor KO143 increased the transfer of (14)C-PhIP from maternal to fetal circulation (FM ratio 0.90+/-0.08 at 6 h, p<0.05) while the ABCC1/ABCC2 inhibitor probenecid had no effect (FM ratio at 6 h 0.75+/-0.10, p=0.84). There was a negative correlation between the expression of ABCG2 protein in perfused tissue and the FM ratio of (14)C-PhIP (R=-0.81, p<0.01) at the end of the perfusion. The expression of ABCC2 protein did not correlate with FM ratio of PhIP (R: -0.11, p=0.76). In addition, PhIP induced the expression of ABC transporters in BeWo cells at mRNA level. In conclusion, our data indicates that ABCG2 decreases placental transfer of (14)C-PhIP in perfused human placenta. Also, PhIP may modify ABC transporter expression in choriocarcinoma cells.

[1]  J. Hitti,et al.  P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  T. Ishikawa,et al.  Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. , 2004, Drug metabolism and pharmacokinetics.

[3]  O. Vuolteenaho,et al.  Gene Structure of a New Cardiac Peptide Hormone: A Model for Heart-Specific Gene Expression1. , 2000, Endocrinology.

[4]  J. Unadkat,et al.  Breast Cancer Resistance Protein 1 Limits Fetal Distribution of Nitrofurantoin in the Pregnant Mouse , 2007, Drug Metabolism and Disposition.

[5]  J. Cerhan,et al.  Well-done meat intake and the risk of breast cancer. , 1998, Journal of the National Cancer Institute.

[6]  K. Turteltaub,et al.  The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans. , 1999, Carcinogenesis.

[7]  D. Barker,et al.  Developmental origins of adult disease , 2007 .

[8]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[9]  Jos H Beijnen,et al.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.

[10]  P. Myllynen,et al.  The fate and effects of xenobiotics in human placenta , 2007, Expert opinion on drug metabolism & toxicology.

[11]  M. S. Miller.  Transplacental lung carcinogenesis: molecular mechanisms and pathogenesis. , 2004, Toxicology and applied pharmacology.

[12]  A. V. Van Gennip,et al.  Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. , 2001, Carcinogenesis.

[13]  P. Kaufmann,et al.  Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). , 2004, Pharmacogenetics.

[14]  S. Ozanne,et al.  Mechanisms of Disease: the developmental origins of disease and the role of the epigenotype , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[15]  O. van Tellingen,et al.  Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. , 1999, The Journal of clinical investigation.

[16]  H. Autrup.  Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. , 2000, Mutation research.

[17]  P. Myllynen,et al.  An examination of whether human placental perfusion allows accurate prediction of placental drug transport: studies with diazepam. , 2002, Journal of pharmacological and toxicological methods.

[18]  M Kulldorff,et al.  2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, a carcinogen in high-temperature-cooked meat, and breast cancer risk. , 2000, Journal of the National Cancer Institute.

[19]  P. Strickland,et al.  Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. , 1998, Carcinogenesis.

[20]  V. Ling,et al.  P‐glycoprotein stability is affected by serum deprivation and high cell density in multidrug‐resistant cells , 1995, Journal of cellular physiology.

[21]  T. Sugimura,et al.  Increased risk of mammary carcinoma development following transplacental and trans-breast milk exposure to a food-derived carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), in Sprague-Dawley rats. , 1995, Cancer research.

[22]  O Pelkonen,et al.  Carbamazepine and Its Metabolites in Human Perfused Placenta and in Maternal and Cord Blood , 1995, Epilepsia.

[23]  B. Sarkadi,et al.  Differential Modulation of the Human Liver Conjugate Transporters MRP2 and MRP3 by Bile Acids and Organic Anions* , 2003, Journal of Biological Chemistry.

[24]  K. Audus,et al.  Controlling drug delivery across the placenta. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  S. Coburn,et al.  Human placental vitamin B6 (pyridoxal) transport: normal characteristics and effects of ethanol. , 1992, The American journal of physiology.

[26]  P. Myllynen,et al.  Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo , 2003, European Journal of Clinical Pharmacology.

[27]  M. Colvin,et al.  Impact of environmental exposures on the mutagenicity/carcinogenicity of heterocyclic amines. , 2003, Toxicology.

[28]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[29]  K. Iseki,et al.  Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[30]  C. Lowik,et al.  Removal of serum factors by charcoal treatment promotes adipogenesis via a MAPK-dependent pathway , 2005, Molecular and Cellular Biochemistry.

[31]  G R Lankas,et al.  Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. , 1998, Reproductive toxicology.

[32]  W. T. Beck,et al.  Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene , 2004, Cancer Research.

[33]  F. Hatch,et al.  The isolation and identification of a new mutagen from fried ground beef: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). , 1986, Carcinogenesis.

[34]  T. Walle,et al.  Transport of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) across the human intestinal Caco-2 cell monolayer: role of efflux pumps. , 1999, Carcinogenesis.

[35]  S. Brennecke,et al.  The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  I. Schoots,et al.  Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. , 2001, Molecular pharmacology.

[37]  L. Hilakivi-Clarke,et al.  Fetal origins of breast cancer , 2006, Trends in Endocrinology & Metabolism.

[38]  U. Kalyoncu,et al.  The breast cancer resistance protein: gatekeeper to the synovium? , 2010 .

[39]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[40]  L. Vaskivuo,et al.  DNA damage caused by benzo(a)pyrene in MCF-7 cells is increased by verapamil, probenecid and PSC833. , 2007, Toxicology letters.

[41]  Jos H Beijnen,et al.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs , 2002, AIDS.

[42]  P. Pávek,et al.  P-glycoprotein in the placenta: expression, localization, regulation and function. , 2006, Reproductive toxicology.

[43]  C. Klaassen,et al.  Regulation of hepatic transporters by xenobiotic receptors. , 2005, Current drug metabolism.

[44]  J. Keelan,et al.  The xenobiotic transporter ABCG2 plays a novel role in differentiation of trophoblast-like BeWo cells. , 2007, Placenta.

[45]  A. Bhattacharyya,et al.  Variable expression of P-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis , 1992, Diseases of the colon and rectum.

[46]  L. Sarkozi,et al.  A new recycling technique for human placental cotyledon perfusion: application to studies of the fetomaternal transfer of glucose, inulin, and antipyrine. , 1983, American journal of obstetrics and gynecology.

[47]  L. Bennett,et al.  PhIP carcinogenicity in breast cancer: computational and experimental evidence for competitive interactions with human estrogen receptor. , 2005, Chemical research in toxicology.

[48]  J. Kingdom,et al.  Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. , 2006, Canadian journal of physiology and pharmacology.

[49]  E. Snyderwine,et al.  DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. , 1999, Carcinogenesis.

[50]  M. Oshimura,et al.  FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA , 2005, Drug Metabolism and Disposition.

[51]  Kirsi Vähäkangas,et al.  Gene transfer to human placenta ex vivo: a novel application of dual perfusion of human placental cotyledon. , 2002, American journal of obstetrics and gynecology.

[52]  Y. Sugimoto,et al.  Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. , 2005, Cancer research.

[53]  J. Keelan,et al.  Active transport across the human placenta: impact on drug efficacy and toxicity , 2006, Expert opinion on drug metabolism & toxicology.

[54]  Alfred H. Schinkel,et al.  Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[55]  J. Kingdom,et al.  Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. , 2006, Placenta.

[56]  N. Illsley,et al.  Effects of chronic hypoxia in vivo on the expression of human placental glucose transporters. , 2006, Placenta.

[57]  T. Sugimura,et al.  Heterocyclic amines: Mutagens/carcinogens produced during cooking of meat and fish , 2004, Cancer science.

[58]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[59]  Kari Laine,et al.  Functional role of P‐glycoprotein in the human blood‐placental barrier , 2005, Clinical pharmacology and therapeutics.

[60]  A. Karlsson,et al.  Transfer of the food mutagen PhIP to foetuses and newborn mice following maternal exposure. , 1994, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[61]  J. Keelan,et al.  Drug Transfer and Metabolism by the Human Placenta , 2004, Clinical pharmacokinetics.

[62]  P. Strickland,et al.  Metabolism of 2-amino-1-methyl-6-phenylimidazo [ 4 , 5b ] pyridine by human cytochrome P 4501 A 1 , P 4501 A 2 and P 4501 B 1 , 1998 .

[63]  P. Sivonen,et al.  Comparison of the formation of benzo[a]pyrene diolepoxide-DNA adducts in vitro by rat and human microsomes: evidence for the involvement of P-450IA1 and P-450IA2. , 1989, Journal of biochemical toxicology.

[64]  Yi Zhang,et al.  Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. , 2006, American journal of physiology. Endocrinology and metabolism.

[65]  O. Vuolteenaho,et al.  Gene Structure of a New Cardiac Peptide Hormone : A Model for Heart-Specific Gene Expression * , 2000 .

[66]  L. Joss-Moore,et al.  The developmental origins of adult disease , 2009, Current opinion in pediatrics.